Member Info for Steadydanny

I recommended this company a month ago. I get nervous at recommending something. But they would be up about 150%. . Green bitcoin technology is a must and a given way forward.

As in 21st October!

"data highlight the combination of PARP and CHK1 inhibitors as a new potential chemo-free strategy to treat MYCN-driven tumors [e.g. childhood neuroblastoma], which might be promptly translated into clinical trials" Sareum $SAR.L #AIM #biotech #Chk1
Thoughts people...oh my

Don't say what they are as that breaks the rules to them being accepted and considered. Just interesting to see who puts forward Qs to a +£200m mc company.

Or just

Hi Potnak. Re your comment about advanced progression for greater value they say this on the last update
The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
So I think we are on the same hymn sheet as they stipulate they are advancing internal programmes re 1801 and 1802. So they are already on it. Atleast that's my take from it.
But they do keep pushing the 737 updates and potential pipeline advancement which Sierra have alluded to.
They also elsewhere mention that FLT3 is open to license which would include the data gathered from the Chinese licensee which the board were going to review re solubility.
So many thoughts
Are we saying to potential partners ok we are continuing with 1801/2 as we are keen to progress and have funds to continue
And 737 has renewed interest from Sierra
And FLT3 re data gathered (not sure about dates) that the Licensee couldn't get to reach targets re milestones set due to solubility....but could this be something to do with the submarine patent?
Just my thoughts. Probably wrong.
Best regards to you and your family .
Steadydanny

Also worth noting the amount of our RNS re PH that involves discussing 737. About two thirds and note the initial paragraph re generate value
About Sareum through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage......so this...pre clinical or early clinical trials!!

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.
Best wishes to all and I feel we have significant news coming that will become apparent to ....maybe the world.?

Hi Boilb. Definitely good things ahead.
A comparison I can make from planning applications and trust me I learnt the hard way and assumed going cheaper would work...No!. If you want a planning application to succeed you employ the best town planners you know which comes at a price but you GET the best results.
PH are not a coincidence and their recent IPO I suggest will want them to be seen as a worthwhile investment themselves. So we become clients.
As Ahfam pointed out they have a holding here.
So much more I could mention imo with relevant backed posts but I will be replete.
Enjoy your posts boilb.
I have my question ready for Q and A. ;-)

Ezzer not sure why you would post those names here.. Completly different fundamentals here. I find your post fits within the basher spectrum.
I would rather you mentioned specifically why you are an investor since 2015 and what drew your attention to sareum to invest. That way then your post might have plausible consideration.

Hi HBD. It's speculation but it's a possibility.
I further refer to the 'published but not officially RNSd' submarine patent that has other names on the patent.
I want to know if the other named individuals (or companies they work for) apart from or including our sareum director are able to work as consultants to 'potential partners' but as it's a sareum patent they are working on so we are always the benefactor re upfront payments and ongoing royalties as it mentions.
It's like we have created multiple sareum subcontractors that could be utilised via ndas to multiple pharmas to work on a drug of ours but see where it goes with their in-house trials.
Highest bid for?
I'm just spell bound by everything happening

Great Post Boilb. And also HBD there was an insider I quoted back along that in DM financial re GSK that said the split of GSK and the now defunct Merck development programmes albeit they are sticking together on ovarian cancer...and that Walmsley needed new pipeline drugs and that would mean they would have to pay top price as big pharmas needed preclinical drugs with potential. Elliott isn't happy as they have atleast a billion newly paid into GSK and wants scientific directors as well.......hmmm
So much going on.
I added again on Friday. I am convinced we are on the verge of major news...multiple news and our Q and A is a way of garnering investor sentiment and knowledge.

Hi HBD Re your comment on multiple licences this is part of our chairman's last statement...

In terms of business development, we are continuing to keep potential partners informed of our progress with a view to securing commercial licences for our TYK2/JAK1 programmes that balance cost and risk with maximising shareholder value. We will, as usual, keep shareholders updated in this regard as appropriate.

Personally I think this was the most telling part of our update....I draw your attention to...
'continuing to keep potential partners informed' that surely substantiates the discussions here of partnerships...and secondly
'view to securing commercial licences'.

Both plurals ......thus multiple interested potential partners for multiple licences!
Best regards Steadydanny

Hi thoth. It's happening as you said..
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.
And then
In a previous discussion, noted by Sareum on 6 August 2021, of the rationale for in-licensing BET inhibitor AZD5153, now known as SRA515, from AstraZeneca, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications. These included potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action. Sierra has also noted that SRA515 has shown preclinical efficacy in combination with a diverse range of agents, and that synergy between SRA515 and a family of DNA damage response agents, known as ATR inhibitors, suggested potential utility in combination with SRA737.
Hello Peel Hunt.
Thoth. Just cheers. Good things and thankyou.

Dr Tim Mitchell, CEO of Sareum, commented:

"Sareum continues to advance the preclinical development of its proprietary dual TYK2/JAK1 inhibitor programmes. We are close to completing the preclinical development of SDC-1801 with the aim of starting the clinical development of this novel compound in the second half of 2022. This is clearly a very important milestone for the Company. In addition, the early preclinical results we have seen with SDC-1801 in our Covid-19 programme suggest that it may have potential to address the hyper-inflammatory response that some patients experience, and we are looking at the next steps to advance development in this indication. We are particularly pleased to have raised substantial additional funding that will be deployed to advance these programmes into clinical development and build a robust data package that will add momentum to our ongoing partnering activities for these exciting and differentiated assets.
So they are deploying said subscriptions themselves and adding to momentum re partnering activities for these exciting and differentiated assets.
Enter PH. Anyone think the trades today looked like further fill orders not reported yet which probably see a blue start on Monday?

Hi Ahfam.
Re your post, which is doing my head in re share additions in a good way :-) is it possible a HNWI could have themselves hidden behind a company? Just some of the numbers with a bit of additional trading look very close to other numbers realised recently.

Reading this and the fact that just over a month later they are not dealing with companies as a bread and butter choice....I believe they are being rather selective .... something big is happening here....so PH
has raised £112m ahead of a float that it will use to expand into Europe and invest in new technology. Peel Hunt's shares will begin trading on AIM on Wednesday at 228p. 

Its bumper listing is set to turn many of its 250 staff into paper millionaires, while chief executive Steven Fine could make £20m from his 7 per cent stake. Fine said he was 'delighted with the positive reception to our IPO, with strong support from institutional investors as well as retail investors'. 

He added: 'I'm also extremely pleased that even more of our dedicated and talented staff are now shareholders following their participation in the employee share offer and would like to thank them for their commitment in making the business the success it is.' 

The decision to go public comes after its earnings have soared amid a frenzy of fundraisings and floats since the pandemic struck. 

Many companies rushed to raise cash during the start of the Covid crisis last year, while more recently there has been a surge in flotations and merger and acquisition activity as worries have eased. 

All of this has proved lucrative for brokers such as Peel Hunt that earn fees for advising their clients on deals and fundraisings.

They want cracking updates to support their IPO.
The timing is almost beyond coincidence.
Best wishes to all Steadydanny

Two positives re FLT3
While the Licensee has improved the bioavailability of the lead compound in the FLT3 programme, it has been unable to achieve the level needed to trigger the milestone under the licensing agreement 
And
Worldwide rights to the FLT3 programme, as well as data relating to progress made by the Licensee, will therefore revert to Sareum.
So we got the data that they researched and paid us £50k for the privilege and we get worldwide rights again.
FLT3 always feels to me like the mystery bonus ball to me.

Hi SOG. Re consolidation discussions here I'm wondering if any could answer this
We have #1 who can exercise £490k of warrants
Then #2 could if sp +9p for +5days =£1m
And #3 could if sp +10.25p +5days =£1.25m
So if (hypothetical) a 100 to 1 consolidation would their warrants available be divided by 100?
And if as I'm reading here a consolidation is not always positive unless we have firm positive confirmed ipr output. So we are hardly going to screw the HNWIs are we.
I'm just guessing we have got PH onboard to assist valuations and dd re multiple interested parties wanting licenses.

We have spent approx £1.6m since 31.12.20 and have £4.4m CAB 30.9.21.
Potential £490k warrants that can be exercised anytime and a further £2.25m if sp greater than 9p and 10.25p + 5 days.
This has been held below 7p!
HNWI 2 and 3 were content to buy at 7p and 8.25p as their research would have seen the price paid at that point satisfied their mc valuation.
We should ask if they could elaborate on the £1.5m r and d paid or is it ndas?
We are worth as it stands minimum 8.25p.
We are worth way more than that now! imo

Take it or leave it as in just a discussion point. The Balkan prophet now deceased predicted a lot of things. Quite remarkable predictions.
Just putting it out there she said cures for cancer would happen in 2021.

Are there any trades?